SRPT Q3 2018 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+70.8% YoY

Gross Profit

$70M88.9% margin

Operating Income

-$70M-89.3% margin

Net Income

-$76M-97.3% margin

EPS (Diluted)

$-1.15

QoQ Revenue Growth

+6.7%

Cash Flow

Operating Cash Flow

-$113M

Free Cash Flow

-$134M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$543M

Stockholders' Equity

$640M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$46M	+70.8%
Gross Profit	$70M	$43M	+62.7%
Operating Income	-$70M	-$46M	-52.7%
Net Income	-$76M	-$48M	-60.0%